BioSpace News Archive

Inipharm today announced that it will be presenting data on the anti-fibrotic effects of one of its small-molecule inhibitors of HSD17B13 in a primary human cell “3D liver-on-a-chip” model of NASH at the American Association for the Study of Liver Diseases’ (AASLD)

Aditxt, Inc. (“Aditxt”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced it has entered into a transaction agreement to reach a definitive agreement by the end of November 2021 to acquire a subsidiary (“AiPharma”) of AiPharma Global Holdings LLC.

In early 2020 when the US Food and Drug Administration (FDA) issued a series of safety alerts on the risk of transmitting SARS-CoV-2 via fecal microbiota transplantation (FMT), the Cambridge-based stool bank OpenBiome was left with freezers full of processed donor stool samples that could not be released until tested for the new virus.

Copenhagen– October 5, 2021 – Orphazyme A/S, a late-stage biopharmaceutical company, announces regulatory updates for its investigational drug candidate, arimoclomol, for which it is seeking marketing authorization in both Europe and the United States for the treatment of Niemann-Pick disease Type C.

CN Bio, a leading Organ-on-a-chip Company (OOC) today announced the commercial launch of its Oncology Service in response to the global need to improve cancer drug discovery approval rates.

For administrative reasons, XVIVO Perfusion has decided to advance the publication of the interim report for the period January - September 2021.

NovaBiotics Ltd announces that the Company will co-sponsor a symposium on new antifungals in which Deborah O’Neil, OBE, Ph.D., FRSE will present an overview of NP339 as a novel peptide therapy candidate for invasive and respiratory fungal disease and Daniel W. Smith, Ph.D. will deliver a poster presentation highlighting the activity profile of NP339 against Aspergillus fumigatus in whole human blood assays at the 10th Congress on Trends in Medical Mycology.

Finch Therapeutics Group, Inc. today announced that Samuel Allen (Al) Hamood has joined Finch’s Board of Directors. Mr. Hamood is an accomplished executive with over 30 years of experience in finance

Johnson & Johnson announced it has submitted data to the U.S. Food and Drug Administration to support use of a booster shot of the Johnson & Johnson COVID-19 vaccine in individuals 18 years of age and older.